Drug Res (Stuttg) 2020; 70(10): 478-483
DOI: 10.1055/a-1223-1734
Original Article

Silibinin Inhibit Cell Migration through Downregulation of RAC1 Gene Expression in Highly Metastatic Breast Cancer Cell Line

Hamed Esmaeil Lashgarian
1  Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Vahid Adamii
1  Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Vajihe Ghorbanzadeh
2  Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Leila Chodari
3  Department of Physiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
4  Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran
,
Fayze Kamali
1  Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Soheila Akbari
5  Department of Obstetrics and Gynecology, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Hassan Dariushnejad
1  Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
2  Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
› Author Affiliations
Funding This study was funded by Deputy of Research and Technology (grant No. 1208), Lorestan University of Medical Sciences, Khorramabad, Iran. The results presented in this work are based on data set of MSc thesis, recorded in Lorestan University of Medical Sciences.

Abstract

Background Triple negative breast cancer is the most invasive breast cancer subtype and possesses poor prognosis and survival. Rho GTPase famil, especially Rac1 participates in a number of signaling events in cells with crucial roles in malignancy, migration and invasion of tumor cells. Silibinin, a flavonoid antioxidant from milk thistle has attracted attention in the recent decades for chemoprevention and chemotherapy of tumor cells. In this study, the effect of silibinin on the migration capacity of MDA-MB-231 cells, a highly metastatic human breast cancer cell line was investigated by evaluation of Rac1 expression.

Method MTT wound healing and transwell assays were performed to evaluate the effects of silibinin on proliferation and migration of MDA-MB-231 cells. In addition, the influence of the silibinin on the expression of Rac1mRNAs was assessed by RT-PCR.

Results Results indicated significant dose-dependent inhibitory effect of silibinin on proliferation and migration of MDA-MB-231 cells. It significantly inhibited the expression of Rac1 mRNA.

Conclusion In conclusion, the results demonstrate that the silibinin can be used as an experimental therapeutic for the management of TNBC metastatic cancer.



Publication History

Received: 18 June 2020

Accepted: 13 July 2020

Publication Date:
13 August 2020 (online)

© 2020. Thieme. All rights reserved.

© Georg Thieme Verlag KG
Stuttgart · New York